🇺🇸

US SEC Filing Intelligence

· daily

Biotech Small-Cap Approvals — April 14, 2026

The FDA's approvals over the April 14, 2026 period (reflecting fallback actions from April 7-9) delivered 6 neutral 'other' approvals with 0 NMEs, 0 biosimilars, 0 label expansions, all carrying medium strength and materiality (5/10). These went to small-cap sponsors AUCTA (FOSFOMYCIN TROMETHAMINE), ASCENT PHARMS INC (MIRABEGRON), ZENARA (ELTROMBOPAG OLAMINE), RENATA LIMITED (Unknown), CHANGZHOU PHARMACEUTICAL FACTORY (VERICIGUAT), and APOTEX INC (SEMAGLUTIDE), each summarized as biosimilar approvals despite classification. No dominant therapeutic area theme emerges amid diverse molecules spanning urology, hematology, cardiovascular, endocrinology, and infectious disease. Highest-conviction signal is APOTEX INC's SEMAGLUTIDE approval, implying neutral commercial entry potential into GLP-1 arena with all key metrics NOT_DISCLOSED. Key risk/watch item: limited pipeline signals from single approvals per sponsor, raising questions on sustained execution.

6 total filings
· daily

Big Pharma Approvals — April 14, 2026

The April 14, 2026 period featured 1 Other approval (0 NMEs, 0 biosimilars, 0 label expansions) in the Big Pharma stream, generating 1 bullish signal. GENENTECH INC secured a label expansion for FARICIMAB-SVOA (VABYSMO), signaling portfolio strengthening though commercial details remain NOT_DISCLOSED. No dominant therapeutic area theme emerges from this single event. Highest-conviction signal is the bullish FARICIMAB-SVOA label expansion by GENENTECH INC, implying extended market reach for the sponsor. Key risk/watch item: monitor post-approval uptake given lack of disclosed peak sales, exclusivity, pricing, or market position data.

1 total filings
· daily

Orphan Drug Approvals — April 14, 2026

The period saw 1 orphan drug approval: 0 NMEs, 0 biosimilars, 0 label expansions, and 1 Other, generating 1 bullish signal with no bearish or neutral outcomes. BRISTOL's AZACITIDINE (ONUREG) fallback approval (noted as label expansion) represents the highest-conviction signal, providing a moderate bullish catalyst (strength 5/10, materiality 5/10) for portfolio diversification in the orphan space. No dominant therapeutic area theme emerges from this single event. Key risk/watch item: limited disclosure on peak sales, exclusivity, pricing, and market position warrants monitoring for commercial uptake and competitive dynamics.

1 total filings
· daily

New Federal Contractors — April 14, 2026

Two new federal contracts totaling $186,887,051 in obligations, with 0/2 defense-related (100% civilian split across State Department and USAID), highlight overseas facilities support and international health services as the dominant theme. The highest-conviction bullish signal stems from Vectrus Systems LLC's $96,674,550 State Department award for Doha, Qatar facilities support, offering ~$32M annual revenue visibility through 2026 (or ~$27M if extended to $137M by 2028). RIGHT TO CARE ZAMBIA LIMITED's $90,212,500 USAID HIV services contract is neutral for equity investors due to its foreign nonprofit status despite $80.3M outlays. A key risk is Vectrus's low $668,474 outlays to date amid $53.6M subawards, warranting monitoring for execution progress.

2 total filings
· daily

Significant Contract Modifications ($10M+) — April 14, 2026

Two significant contract modifications totaling $186,887,051 in obligations, both civilian with zero defense exposure, highlight Department of State and USAID investments in international services. The highest-conviction bullish signal stems from Vectrus Systems LLC's $96.7M Department of State award for facilities support in Doha, Qatar, offering multi-year revenue visibility up to $137M through 2028 if options are exercised. RIGHT TO CARE ZAMBIA LIMITED's $90.2M USAID HIV services contract is neutral for investors due to its nonprofit status and foreign ownership, despite high $80.3M outlays. Dominant theme is sustained civilian agency funding for overseas program management. Key watch item: Vectrus outlay progress beyond current $668K amid $53.6M subawards, signaling execution risk.

2 total filings
· daily

Contract Deobligations Alert — April 14, 2026

Two civilian agency contract deobligations totaling $186,887,051 were flagged for the period April 14, 2026, with zero defense-related awards, highlighting State Department and USAID facilities and health services themes. The highest-conviction bullish signal stems from Vectrus Systems LLC's $96,674,550 Department of State delivery order for Qatar facilities support, offering multi-year revenue visibility up to $137M with options despite low $668,474 outlays to date. RIGHT TO CARE ZAMBIA LIMITED's $90,212,500 USAID HIV services contract remains neutral for investors as a foreign-owned nonprofit with $80.3M already outlayed. Dominant themes are sustained civilian international program management, but low execution on the top contract poses execution risk. Key watch item: Vectrus outlay progress beyond $668,474 and option exercises toward 2026-04-30 or 2028-04-30 end dates.

2 total filings
· daily

Contract Option Exercises — April 14, 2026

Two civilian contract option exercises totaling $186,887,051 in obligations provide limited defense exposure (0/2 defense-related) with average signal strength of 4.0/10. The highest-materiality award is a bullish $96.7M obligation to Vectrus Systems LLC from the Department of State for facilities support in Doha, Qatar, offering multi-year revenue visibility up to $137M potential through 2028. USAID's $90.2M obligation to foreign nonprofit Right to Care Zambia Limited for HIV services is neutral due to its low materiality and nonprofit status limiting equity implications. Dominant theme is international civilian services support outside DOD priorities. Highest-conviction signal is bullish multi-year visibility for Vectrus amid low execution risk via cost-plus-fixed-fee structure. Key watch item is Vectrus outlay progress beyond current $668,474 amid $53.6M subawards.

2 total filings
· daily

Federal Professional Services Contracts — April 14, 2026

USAID/Zambia obligated $90,212,500 across one federal professional services contract to RIGHT TO CARE ZAMBIA LIMITED, representing 0% defense-related activity in the period. The dominant agency and sector theme is USAID international health funding for HIV prevention and treatment under the MECH program. The highest-conviction signal is neutral (strength 2/10, materiality 1/10) due to the recipient's status as a foreign-owned nonprofit with limited public equity implications. $80,280,560 has already been outlayed of the $90.2M obligation, with a ceiling of $121,447,869 including options. Key watch item: option exercises to expand beyond current obligation levels through performance end date of June 23, 2028.

1 total filings
· daily

High-Value Federal Grants ($5M+) — April 14, 2026

Two high-value civilian federal contracts totaling $186,887,051 in obligations were analyzed, with 0/2 defense-related and an average signal strength of 4.0/10. The dominant agencies are Department of State and USAID, focusing on international facilities support in Qatar and HIV prevention/treatment in Zambia. Highest-conviction bullish signal stems from Vectrus Systems LLC's $96,674,550 State Department award, offering multi-year revenue visibility estimated at ~$32M annually through 2026-04-30 or ~$27M if extended to $137M by 2028-04-30. RIGHT TO CARE ZAMBIA LIMITED's $90,212,500 USAID contract is neutral for equity investors as a foreign-owned nonprofit with $80.3M already outlayed. Key watch item: Vectrus Systems LLC outlay progress beyond current $668,474 amid high $53.6M subawards.

2 total filings
· daily

General Federal Contracts — April 14, 2026

Two civilian contracts totaling $186,887,051 in obligations were analyzed, with 0/2 defense-related, focusing on overseas support services via the Department of State and USAID. The highest-conviction signal is bullish on Vectrus Systems LLC's $96,674,550 Department of State delivery order for facilities support in Doha, Qatar, providing multi-year revenue visibility up to $137 million with options through 2028. RIGHT TO CARE ZAMBIA LIMITED's neutral $90,212,500 USAID contract for HIV services in Zambia carries limited equity implications as a foreign-owned nonprofit with $80.3 million already outlayed. Dominant theme is sustained civilian agency demand for international program management. Key watch item: Vectrus outlay progress beyond current $668,474 amid high $53.6 million subawards.

2 total filings
· daily

S&P 500 Technology Sector SEC Filings — April 14, 2026

Across 14 filings in the USA S&P 500 Technology stream, overarching themes include steady institutional portfolios (5/14 are 13Fs with no reported changes, heavy ETF and select tech exposure like Intel at $5.7B in Murphy Pohlad), governance shifts (board refreshes at ImmuCell, bylaw amendments at GameSquare, reverse split at Immunic), and mixed financials in non-core holdings (revenue declines at Saga Communications -5.1% YoY, loss narrowing at Bravo -41% expense cut). Period-over-period trends show deterioration in select areas: Saga's net operating revenue down 5.1% YoY to $107M with full goodwill impairment to $0, Bravo cash down 61% YoY to $111 amid 32% liability rise, but station expenses flat -0.1% at Saga. Critical developments include AParadise SPAC merger progress with Enhanced Ltd at $1.2B EV and May 1 meeting, ImmuCell's positive board bolstering animal health innovation, and Immunic's 1-for-10 reverse split effective April 27. Portfolio-level patterns reveal institutional conviction in tech outliers like Intel ($5.7B top holding) and Cisco ($1.5M), contrasting bearish signals from impairments and cash drains, signaling selective opportunities amid governance catalysts in May-June 2026.

6 high priority 8 medium 14 total filings
· daily

Nasdaq 100 Stocks SEC Filings — April 14, 2026

Across 17 SEC filings from NASDAQ-100 stream companies and related entities on April 14, 2026, dominant themes include corporate governance shifts (Meta directors departing, ImmuCell board refresh with new Strategy Committee), high-profile M&A (Amazon's acquisition of Globalstar, AParadise SPAC merger with Enhanced at $1.2B EV), and mixed annual results (Saga revenue -5.1% YoY to $107M with $20M+ impairments driving net loss -$1.22 EPS vs +$0.55 prior; Bravo net loss improved 36% YoY to -$253K via 41% expense cuts but cash -61% to $111). Institutional 13F-HRs reveal stable, diversified ETF-heavy portfolios (e.g., Murphy Pohlad $279B AUM with Intel/Chevron tops, no changes noted). Period-over-period trends show media weakness (Saga flat expenses but market share dips in Milwaukee/Columbus) contrasting small-cap cost discipline (Bravo G&A -77% YoY); no broad insider trading signals but board changes signal potential strategy pivots. Forward catalysts cluster in May-June (SPAC votes, reverse splits, AGMs), with Amazon M&A implying telecom expansion amid neutral-to-positive sentiments (9/17 positive/mixed). Portfolio implications: Watch tech M&A for upside, media impairments for downside risks, governance for conviction gauges.

9 high priority 8 medium 17 total filings
· daily

S&P 500 Financials Sector SEC Filings — April 14, 2026

Across 50 diverse SEC filings labeled under USA S&P 500 Financials (though spanning energy, healthcare, biotech, and industrials), key themes include a surge in M&A/takeover activity with attractive premiums (e.g., Avanos +72%, Day One $21.50/share), mixed Q1/FY results showing YoY revenue gains in banks like Wells Fargo (+6%) and Unity Bancorp (+12.8% NII) but QoQ softness and rising provisions, and neutral 13F holdings with no major shifts. Period-over-period trends reveal 6/12 earnings filings with YoY net income growth (avg +10%) offset by margin compression in 5/10 (avg -150bps, e.g., AstroNova -7.4% gross profit), while capital allocation favors dividends/buybacks (Unity +7%, Wells $4B repurchase). Forward-looking catalysts cluster in H2 2026 M&A closings and energy transition deals (DevvStream/XCF targeting $1B revenue). Portfolio-level, financials show loan/deposit growth (Unity +10.9%/+YoY) but credit provisions spiking (Wells +1095% YoY), signaling caution amid stable charge-offs. Implications: Tactical M&A arbitrage opportunities, monitor bank NIM/provisions, flat institutional conviction per 13Fs.

21 high priority 29 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — April 14, 2026

Across 50 filings in the USA S&P 500 Consumer Staples intelligence stream (with broader financial and operational crossovers), dominant themes include strong YoY revenue and net income growth in major financial institutions like JPMorgan (+13% NI, +10% revenue), BlackRock (+27% revenue, $130B inflows), and Wells Fargo (+7% NI, +15% EPS), offset by rising credit provisions (Wells +1093% YoY) and mixed segment results. Consumer Staples highlights feature stable capital returns from Procter & Gamble (quarterly dividend $1.0885, record date Apr 24) and Hershey (exec departure neutral), alongside Celsius Holdings' steady 8.6-8.97% insider ownership amid proxy battles. Small-cap operators show sharp declines, e.g., Greystone Logistics sales -45% YoY 9M to $22M, Nature's Miracle revenue -97.6% YoY Q3, and Chipmos net profit -61.7% YoY amid margin compression to 10.8%. Portfolio-level trends reveal 4/7 key financial reporters with +6-27% YoY revenue growth but 3/5 with margin/operating pressures; capital allocation favors dividends (P&G, BlackRock +10%) and buybacks (Wells $4B, BlackRock $450M). Board/governance changes prevalent in 12/50 filings (e.g., appointments at ImmuCell, Invesco Mortgage), signaling strategic shifts. Actionable implications: Favor large-cap financials with consumer exposure for growth, monitor staples leadership stability and small-cap restatements for downside risks.

18 high priority 32 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — April 14, 2026

Across 50 filings in the USA S&P 500 Industrials stream, 13F-HR reports dominate (e.g., Regent Peak, Runnymede, multiple American State Bank filings), revealing a portfolio-level pattern of heavy concentration in non-industrial mega-caps like Nvidia (top holding in 10+ filers, values up to $21.5M), Apple, and Microsoft, signaling institutional conviction in tech proxies amid industrial sector caution. Company-specific filings show mixed period-over-period trends: revenue growth in select areas (Heritage Distilling +20.4% YoY total net revenues, Unity Bancorp loans +10.9% YoY) contrasted by declines (Saga Communications -5.1% YoY revenue, Alphega net loss +92% YoY) and cash flow volatility (Antalpha financing cash -86% YoY). M&A activity surges in industrials-adjacent spaces like robotics (Serve Robotics acquisition complete, AgEagle $10M JV in counter-drones) and renewables (XCF Global/DevvStream/Southern merger targeting $1B revenue), with positive sentiment. Capital allocation mixed: dividend hikes (Unity +7% to $0.16, Ohio Valley $0.25) vs cuts (Saga -37.5% to $1.00). Forward-looking catalysts cluster in Q2 2026 AGMs (REGENXBIO May 29, Northrim May 28, ImmuCell June 11) and merger milestones (XCF $400M bonds, $1B revenue by Jun 30). Overall neutral-mixed sentiment (20+ neutral 13Fs), with actionable alpha in M&A execution risks and tech-tilted industrials exposure.

20 high priority 30 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — April 14, 2026

Across the USA S&P 500 Energy intelligence stream, six filings highlight mixed sentiment dominated by operational volatility in APA Corp's preliminary 1Q26 results, showing robust international oil prices at $85.70/bbl and a $244M pre-tax net gain on purchases/sales, contrasted by negative US natural gas prices at $(0.35)/Mcf triggering 88 MMcf/d gas and 6,800 bbl/d NGL curtailments. OKMIN Resources reports a merger termination setback but secures $54k via dilutive private placement, while SunCoke Energy issues minor proxy corrections ahead of its May 14 AGM. Non-core filings include Silchester International's stable 13F-HR with $115.6B portfolio heavily tilted to non-energy names like Nutrien ($98.8B position), and AParadise Acquisition Corp's advancing $1.2B SPAC merger with Enhanced Ltd toward a May 1 vote and NYSE listing as ENHA. Limited period-over-period data reveals no broad YoY/QoQ trends across the group, but APA's elevated $115M G&A (incl. $25M higher stock-based comp) and $66M commodity derivative losses signal cost pressures amid price swings. Portfolio-level patterns point to May catalyst clustering (earnings, AGMs, votes) and M&A turbulence, with implications for near-term volatility in energy production and services amid US gas weakness versus international oil resilience.

3 high priority 3 medium 6 total filings
· daily

US Material Events SEC 8-K Filings — April 14, 2026

Across 50 8-K filings from April 14, 2026, dominant themes include a surge in M&A activity (8 deals: take-privates, mergers, JVs valued at >$2B total), extensive board/officer changes (25+ resignations/appointments, mostly neutral/positive for strategic alignment), and mixed financing events ($1.5B+ raised via equity/debt/credit but 4 distress signals). Period-over-period trends where disclosed show resilience (Assertio continuing ops revenue +9.7% YoY to $68.2M despite wider $31.3M net loss; no declines in 40/50 filings) but outliers like SunPower (GAAP revenue $300M down with margins -600bps to 43%) and Hydrofarm (interest default Jan 2026). Critical developments: Avanos 72% premium takeover ($1.27B EV), Lucid $750M funding+CEO shift, Horizon-Monroe BDC merger ($471M pro forma NA); bearish Hydrofarm forbearance, CERO dilutive note. Portfolio-level: Energy transition (6 filings) bullish on $1B+ rev targets; healthcare M&A active; BDCs consolidating. Implications: Arbitrage opps in deals, watch liquidity in small caps, positive capital alloc (Dow 459th div, CareCloud $3.2M savings).

50 high priority 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — April 14, 2026

Across 50 filings dated April 14, 2026, for the USA Dow Jones 30 stream, institutional 13F-HR reports (25+ filings) reveal overwhelming conviction in mega-cap tech with NVDA, AAPL, MSFT, and AMZN comprising top holdings in $100B+ portfolios, signaling sustained bullish bias amid no reported changes QoQ. Blue-chip earners show resilience: JNJ Q1 sales +9.9% YoY (raised FY2026 guidance to $100.8B, +7%), JPM net income +13% YoY ($16.5B), but mixed EPS/FCF trends (JNJ GAAP NI -52%). Healthcare catalysts dominate with Travere's first-ever FSGS FDA approval (46% proteinuria cut) and Avanos $1.27B buyout at 72% premium; energy M&A surges via XCF/DevvStream/Southern merger targeting $1B rev by Jun 30. Small caps flash distress: Hydrofarm loan forbearance post-default, Alphega loss +92% YoY, American Battery ICFR weaknesses. Capital allocation favors dividends (Unity +7%, Dow 459th consecutive $0.35, Ohio Valley $0.25). Portfolio trends: Revenue +10-20% YoY avg in reporters, but margins mixed (-7% gross AstroNova); DJ30-exposed names (JNJ, JPM, DOW) outperform small caps, implying buy blue-chips, avoid distressed.

17 high priority 33 medium 50 total filings
· daily

US SEC Filings Daily Market Digest — April 14, 2026

Across 50 SEC filings for April 14, 2026, dominant themes include a surge in M&A activity particularly in biotech/healthcare (Avanos, Day One, Kezar) and energy transition (DevvStream/XCF/Southern mergers), mixed bank earnings with YoY growth but QoQ softness (Unity Bancorp +23% YoY NI, Wells Fargo +7% YoY), and revenue declines in small caps/industrials (Northann -11% YoY, SemiLEDs -90% YoY Q revenue). Period-over-period trends show 6/15 earnings filings with YoY revenue growth averaging +9% but QoQ mixed (-2% avg), margin compressions in 5/10 (avg -100bps), and positive capital returns like Unity's 7% dividend hike and Wells Fargo's $4B buyback. Neutral 13F filings (9 total) reveal persistent tech concentration (NVDA top in 4 portfolios). Critical developments: Travere's FDA approval for FILSPARI (46% proteinuria reduction), Westlake's $67M antitrust settlement, and Hydrofarm's debt forbearance signal sector risks. Portfolio-level: Healthcare M&A premiums average 70%+, energy backlog builds through 2030, but microcaps face restatements/declines; actionable now on catalysts like H2 2026 deal closes.

21 high priority 29 medium 50 total filings